Back to search
FDAFDA · Food and drugs·Recall number Z-2210-2023

RET Distal Probe. Used in Fluorescence in situ hybridization (FISH), a laboratory technique for detecting and locating a specific DNA sequence on a chromosome.

Published July 26, 2023 · Recall initiated: May 24, 2023

Summary

FDA records medical device Class II recall Z-2210-2023, published July 26, 2023 and initiated May 24, 2023. Recalling firm: Cytocell Ltd.; Status: Ongoing; Reported quantity: 61 units; Lot: Catalog No. LPS509-A; UDI-DI: 05055844900516; Lot No. 076764, 080124, 082129, 082560, 083247, 083550, 083850. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

DNAs used during the manufacture of two affected models were accidentally inverted during manufacturing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cytocell Ltd.
Distributor
US Nationwide distribution in the states of CA, FL, OH, & SC.
Lot
Catalog No. LPS509-A; UDI-DI: 05055844900516; Lot No. 076764, 080124, 082129, 082560, 083247, 083550, 083850.
Risk classification
Class II
Area (FDA)
device
Country
United Kingdom

Related recalls

Questions about this recall

Was RET Distal Probe. Used in Fluorescence in situ hybridization (FISH), a laboratory technique for detecting and locating a specific DNA sequence on a chromosome. recalled?

Yes. FDA published recall Z-2210-2023 on July 26, 2023. Reported hazard: DNAs used during the manufacture of two affected models were accidentally inverted during manufacturing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter